Biomarker-based surrogate endpoints can accelerate development timelines – but only when the evidence, pathway and expectations are aligned. In the latest issue of Drug & Device World ICON’s Elizabeth Madichie and Jack ...
Medical Imaging
Integrated solutions based on the science of imaging biomarkers
Improving decision making, increasing efficiency and potentially reducing trial costs
ICON Medical Imaging experience in the last five years:
-
990
Clinical trials -
230,443
Patients -
32,191
Sites
Medical imaging endpoints can play a critical role in assessing patient safety, treatment efficacy and disease progression. ICON’s end-to-end imaging solutions support consistent acquisition, secure data management and expert analysis across global clinical trial sites, leveraging AI-enabled analysis to help accelerate insights.
Combining scientific expertise, operational delivery and secure technology platforms, we help sponsors reduce imaging-related delays, support evidence-based decision-making and meet stringent regulatory requirements.
Our team of more than 450 qualified clinical imaging professionals includes radiologists, imaging scientists and certified imaging technologists who advise on imaging endpoints and support the medical, scientific and regulatory needs of clinical trials.
As part of one of the world's largest global CRO’s we have access to a wealth of operational and scientific resources. When you partner with ICON you will benefit from:
-
Global access to over 1,200 trained radiologists across imaging modalities.
-
High-quality imaging data supported by training and site engagement.
-
Integrated scientific support, including data management and medical writing.
- Oncology Experts in the complex world of clinical trial oncology response criteria implementation
- Cardiovascular Experience in all cardiovascular indications and imaging modalities
- Central nervous system Clinical trial imaging study experience across a variety of central nervous system diseases
- Metabolic disease Advanced imaging expertise for metabolic diseases
- Obesity weight loss Expertise in imaging and analysis for obesity weight loss research
- MASLD/MASH Multi-modal image acquisition and processing expertise in MASLD/MASH and obesity assessments
- Collect and hold Collect and hold in early phase imaging clinical trials
- Rescue studies Seamless take over and delivery of image analysis results according to your trial schedule.
- Technology platforms Leading edge technology to streamline the collection, management and analysis of images during clinical trials.
Oncology
Experts in the complex world of clinical trial oncology response criteria implementation
Explore
Cardiovascular
Experience in all cardiovascular indications and imaging modalities
Explore
Central nervous system
Clinical trial imaging study experience across a variety of central nervous system diseases
Explore
Metabolic disease
Advanced imaging expertise for metabolic diseases
Explore
Obesity weight loss
Expertise in imaging and analysis for obesity weight loss research
Explore
MASLD/MASH
Multi-modal image acquisition and processing expertise in MASLD/MASH and obesity assessments
Explore
Collect and hold
Collect and hold in early phase imaging clinical trials
Explore
Rescue studies
Seamless take over and delivery of image analysis results according to your trial schedule.
Explore
Technology platforms
Leading edge technology to streamline the collection, management and analysis of images during clinical trials.
Explore
End-to-end support for all critical components of your imaging study:
|
|
|
Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
This whitepaper compares the use of imaging biomarker methodologies such as RECIST 1.1 with novel tumour growth rate (TGR) modelling. Using this methodology eliminates the need for a comparable control arm which can reduce research costs. TGR modelling also more efficiently captures heterogeneous tumour measurements and whole-body tumour burden.
Find out more:
Discover how ICON Medical Imaging can improve decision making, increase efficiency and potentially reduce costs within your clinical trials.
